Treating Schizophrenia by Correcting Abnormal Brain Development

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Schizophrenia

Interventions

DRUG

Tiagabine

Up to 36 mg daily

DRUG

Placebo

Trial Locations (1)

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

collaborator

Dartmouth-Hitchcock Medical Center

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER